Skip to main content
Article
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
The Lancet (2017)
  • Peter Nash, University of Queensland
  • Bruce Kirkham, Guy's and St Thomas' NHS Foundation Trust
  • Masato Okada, International University, Cambodia
  • Proton Rahman, St. John's University
  • Benard Combe
  • Gerd-Ruediger Burmester, Charité
  • David H Adams, Eli Lilly and Company
  • Lisa Kerr, Eli Lilly and Company
  • Chin Lee, Eli Lilly and Company
  • Catherine L Shuler, Eli Lilly and Company
  • Mark Genovese, Stanford University
  • Khalid Ahmed
  • Jeffrey Alper
  • Nichol Barkham
  • Ralph E. Bennett
  • Francisco Javier Blanco García
  • Ricardo Blanco Alonso
  • Howard B. Blumstein
  • Michael S. Brooks, University of Cambridge
  • Gerd-Rüdiger Burmester, Charité
  • Patricia Cagnoli
  • Paul H. Caldron
  • Alain Cantagrel
  • Der-Yuan Chen
  • Melvin A. Churchill, University of Nebraska Medical Center
  • Christine E. Codding
  • Peter M.G. Deane
  • Jose Del Giudice
  • Atul A. Deodhar, Oregon Health & Science University
  • Rajat K. Dhar
  • Eva Dokoupilova
  • Rita M. Egan
  • Andrea Everding
  • Eva Galíndez
  • David H. Goddard
  • Alice Gottlieb, New York Medical College
  • Philippe Goupille
  • Robert M. Griffin
  • Ramesh C. Gupta
  • Stephen Hall, Monash University
  • Kalpita Hatti
  • Mary P. Howell
  • Yu-Huei Huang, Chang Gung University
  • Ramina Jajoo
  • Namieta M. Janssen
  • Uta Kiltz
  • Alan J. Kivitz, Cedars-Sinai Medical Center
  • Steven J. Klein
  • Mariusz P. Korkosz
Publication Date
January 6, 2017
DOI
10.1016/S0140-6736(17)31429-0
Citation Information
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, et al.. "Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial" The Lancet Vol. 389 Iss. 10086 (2017) p. 2317 - 2327
Available at: http://works.bepress.com/philip-mease/78/